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 “TSH ≥ 2.5mU/l in early pregnancy; prevalence and subsequent outcomes” 
David M Carty, Flora Doogan, Paul Welsh, Anna F Dominiczak, Christian Delles 
Objective 
There remains controversy over how women with abnormal thyroid function tests in pregnancy 
should be classified. In this study we assessed the proportion of women with thyroid stimulating 
hormone (TSH) ≥2.5mU/l in a large obstetric cohort, and examined how many have gone on to 
develop thyroid disease in the years since their pregnancy.  
Study Design  
4643 women were recruited and samples taken in early pregnancy between 2007 and 2010. Thyroid 
function tests were analysed in 2014; in women with raised TSH computerised health records and 
prescription databases were used to identify thyroid disease detected since pregnancy.  
Results 
58 women (1.5%) had a TSH over 5mU/l and 396 women (10.3%) had TSH between 2.5 and 5mU/l. 
Women with TSH>5mU/l delivered infants of lower birthweight than those with TSH<2.5mU/l; there 
were no other differences in obstetric outcomes between the groups. Of those who have had 
thyroid tests since their pregnancy, 78% of those with TSH>5mU/l and 19% of those with TSH 
between 2.5 and 5mU/l have gone on to be diagnosed with thyroid disease.  
Conclusions 
Using a TSH cut-off of 2.5mU/l in keeping with European and US guidelines means that over 12% of 
women in this cohort would be classified as having subclinical hypothyroidism. Treatment and 
monitoring of these women would have major implications for planning of obstetric services. 
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Pregnancy has a significant impact on thyroid metabolism. A number of factors contribute, including 
increased thyroid binding globulin levels,1 the interaction of human chorionic gonadotrophin (β-hCG) 
with thyroid stimulating hormone (TSH), 2 placental deiodinase activity, and altered urinary iodine 
excretion.3  Although the foetus can concentrate iodine and synthesise thyroid hormone from 10-12 
weeks,4  it is mainly reliant upon the transfer of maternal thyroid hormone until approximately 20 
weeks of gestation.5  
 
As a result most women with hypothyroidism, particularly those with previous surgery or radioactive 
iodine therapy, will require an increase in thyroxine dose in pregnancy. Many laboratories have 
developed trimester-specific reference ranges for TSH, but where such reference ranges are not 
available, the American Thyroid Association and the Endocrine Society recommend an upper limit of 
2.5 mU/l in the first trimester, 3 mU/l in the second trimester and 3.5 mU/l in the third trimester.6,7  
 
Subclinical hypothyroidism (SCH) refers to those with a TSH above the reference range, but with 
normal fT4 levels. How to define and whether to treat SCH in pregnancy has been an area of 
increasing debate in recent years. The American Thyroid Association guidelines (2011) define SCH in 
pregnancy as TSH >2.5mU/l with normal fT4  levels, and recommend that women with SCH be 
treated if they have detectable thyroid peroxidase antibodies 7. The Endocrine Society (2012) and 
the European Thyroid Association (2014) recommend treatment of pregnant women with TSH >2.5 
mU/l regardless of their antibody status6,8, while the American College of Obstetrics and Gynecology 
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(ACOG, 2015) do not recommend treatment of SCH in pregnancy. 9 Most of the reported benefits of 
treatment of SCH have been in the setting of assisted conception clinics 10 or in women who have 
detectable thyroid peroxidase antibodies. 11 In general obstetric populations, however, clear 
evidence of the benefits of treating SCH is lacking; two large studies in which women were screened 
and treated for SCH where identified, did not find any difference in the primary outcome, the IQ of 
the offspring. 12 13 
 
The overall aim of this study was therefore to determine how many women have a TSH above 
2.5mU/l in a large low-risk obstetric cohort; our hypothesis was that a significant proportion of 
women would fall into this category and according to guidelines would require treatment. We 
compared pregnancy outcomes in these women to women with TSH < 2.5mU/l. We also investigated 
whether women with elevated TSH in pregnancy have gone on to develop thyroid disease during 5 




Material and Methods 
 
The Proteomics In Pre-eclampsia (PIP) study was conducted between 2007 and 2010. The study 
aimed to develop a proteomic biomarker pattern for the prediction of pre-eclampsia in otherwise 
healthy pregnant women and has been described in detail elsewhere 14; in brief 4643 low-risk 
pregnant women were recruited at their initial antenatal appointment in hospitals across the West 
of Scotland. The study originally was powered to recruit 100 pre-eclampsia cases; based on an 
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estimated prevalence of 2.5% it aimed to recruit at least 4000 women. Women with known chronic 
medical problems, including pre-existing diabetes, chronic hypertension, renal disease, epilepsy and 
hyperthyroidism, were mainly seen in specialist medical obstetric clinics, and were not recruited for 
the PIP study. Women were recruited at gestational week 12-14 and women were followed until 
delivery where information on pregnancy outcomes was obtained from hospital databases. 
Birthweight was corrected for maternal height, weight, ethnicity, gestation at delivery, infant sex 
and parity using customised centile charts (Perinatal Research Institute, http://www.gestation.net).  
Plasma samples were stored in -80C freezers until defrosting for the current analysis. 
 
For the analyses reported here, all available plasma samples from gestational week 12-14 in the PIP 
study were used. TSH and free thyroxine (fT4) levels were analysed in 2014 using automated 
clinically validated platforms (e411, Roche, Burgess Hill, UK) using the manufacturer’s calibrators and 
quality control material. For the purpose of this study, women were classified into three groups; 
those with TSH level of greater than 5mU/l with fT4 levels either within or below the non-pregnant 
reference range (9-21pmol/l), those with a TSH level between 2.5 and 5 mU/l but with free thyroxine 
within the normal range, and those with TSH levels of less than 2.5 mU/l. These cut-offs were chosen 
since 5mU/l is the upper limit of the local (non-pregnant) reference range, and 2.5mU/l is the level 
at which many guidelines recommend treatment of SCH in pregnancy.  
TFTs were analysed some years after pregnancy; women found to have had TSH ≥2.5mU/l in the 
index pregnancy were therefore mainly undiagnosed and untreated during the index pregnancy. We 
used the Community Health Index (CHI) number, a 10-digit unique patient identifier based upon date 
of birth (NHS Scotland) which facilitates the linkage of all electronic medical records to determine 
whether women with TSH greater than 2.5mU/l in pregnancy have gone on to develop thyroid 
disease in the years since their pregnancy. We accessed computerised health records and laboratory 
results (Clinical Portal, NHS Greater Glasgow and Clyde), GP referral letters and prescription 
 6 
databases (NHS Scotland) in 2015 to identify whether women had been given a diagnosis of thyroid 
disease, had attended a GP or hospital clinic for treatment of thyroid disease, had received a 
medication for thyroid disease, or had thyroid tests in the years since their pregnancy.  
Statistical analyses were undertaken using SPSS version 22 (SPSS, IBM, USA). Data are expressed as 
mean [lower and upper bounds of 95% confidence interval] for normally distributed data or as 
median [inter-quartile range] for non-normally distributed data. Normality of data was assessed 
using the Kolmogorov-Smirnov test and by manual inspection of Q-Q normality plots.   Comparisons 
between groups were made using Student’s T-tests for normally distributed data, and by non-
parametric tests for non-normally distributed data.  Categorical variables were compared using Chi-
square tests with measurement of odds ratio.   
All women gave written informed consent for both the study and for follow up of health records. 
The study was approved by the West Glasgow Research ethics committee (07/S0709/79) and the 
study adhered to the principles of the Declaration of Helsinki.  
 
 
Results   
 
An outline of the overall study design is shown in Figure 1. A total of 4643 women were recruited to 
the study at gestational week 12-14 at hospitals across Glasgow and Ayrshire. 88 women were 
known to have had a history of hypothyroidism and were analysed separately, while for 723 women 
there was no plasma remaining for thyroid function testing.  
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There were therefore thyroid tests available for 3832 women who were not known to have had 
thyroid disease.  Median TSH level was 1.3 [inter-quartile range 1.06], mean fT4 level was 14.399 ± 
standard deviation 2.26 (95% confidence interval 14.33, 14.47). Manufacturer quality control 
materials yielded low and high control coefficients of variation which were 2.9% and 3.1% for fT4 and 
5.5% and 6.1% for TSH respectively between runs.  
 
 58 women had TSH above 5mU/l (1.5%), 396 had TSH between 2.5 and 5mU/l (10.3%), and 3378 
had TSH less than 2.5 mU/l (88%). Of the 3378, 6 women had isolated hypothyroxinaemia, with a 
free thyroxine below the non-pregnant reference range (< 9 pmol/l) but with normal TSH levels; 
these women were not included in the analysis. 
 
Pregnancy outcomes are shown in Table 1. Delivery data was not available for 381 of the women. 
Women in whom delivery information was not available were younger than those in the remainder 
of the study cohort (28 years ± 7.8 vs 29 years ± 6.1, p=0.001). There were no other differences 
observed; characteristics of women for whom delivery information was not available are shown in 
Supplementary Table 2.  
 
Women with TSH greater than 5mU/l delivered infants of lower birthweight than those with TSH 
below 2.5mU/l (mean corrected birthweight centile 37.1±30 vs 44.1±30, p=0.02). There were no 
differences in any other obstetric outcomes observed when comparing women with TSH>5mU/l, 
women with TSH 2.5-5mU/l and women with TSH<2.5mU/l (Table 1). There was no correlation 




Computerised health records were used in 2015 to examine what has happened to women with 
TSH≥2.5mU/l in the 4-6 years since the index pregnancy. 58 women were found to have TSH greater 
than 5mU/l at gestational week 12-14. Of these 1 woman developed typical symptoms and was 
diagnosed with hypothyroidism and treated with thyroxine during pregnancy, 13 have been 
diagnosed and treated for hypothyroidism since their pregnancies, 1 has been diagnosed with 
Graves’ disease, 3 women  have had raised TSH on repeat testing but do not appear to have been 
formally diagnosed or treated, while 5  have had normal thyroid function testing. The 35 remaining 
women have not, as far as we can ascertain, had thyroid function testing, or been started on any 
thyroid medications in the years since pregnancy.  
 
396 women were found to have TSH between 2.5 and 5mU/l during their pregnancy. None were 
diagnosed with thyroid disease during their pregnancy, but 16 have been since diagnosed and 
treated for hypothyroidism. 21 have had raised TSH but do not appear to have had a formal 
diagnosis of (or treatment for) hypothyroidism, 4 had postpartum thyroiditis with subsequent 
normal thyroid function tests, 179 have had normal TFTs, 2 have developed Graves’ disease, while 
the remainder do not appear to have had thyroid function testing performed in the years since their 
pregnancy.   
 
88 women in the study were known to have had a history of hypothyroidism prior to the index 
pregnancy; these women were analysed separately. Of them, 23 (26%) had a TSH greater than 
5mU/l at gestational week 12-14, 24 (27%) had a TSH of between 2.5mU/l and 5 mU/L, and 41 (47%) 
had a TSH of less than 2.5 mU/L.  Pregnancy outcomes for these women are shown in 
Supplementary table 3. In women with identified and treated hypothyroidism before pregnancy, 
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pregnancy outcomes were similar in all groups regardless of measured TSH in early pregnancy, and 






The overall aim of this study was to determine how many women in a large healthy pregnant 
population had a TSH over 2.5mU/l, which would be defined according to guidelines as SCH. We 
then aimed to determine how many of these women have gone on to develop thyroid disease in the 
years since their pregnancy.  
 
Thyroid function tests from gestational week 12-14 were retrospectively analysed. After excluding 
women with known thyroid disease we found that 1.5% of women had TSH greater than 5mU/l, and 
10.3% of women had TSH between 2.5 and 5mU/l. Women with TSH > 5mU/l delivered infants of 
lower birthweight than those with TSH < 2.5mU/l but there were no other differences in obstetric 
outcomes.  
 
Of the women found to have had TSH>5mU/l, 31% (78% of those who have been tested) have gone 
on to develop thyroid disease, or have had abnormal tests in the 5 years since their pregnancy. Of 
the women with TSH between 2.5 and 5mU/l, only 11% (19% of those who have been tested) have 
gone on in the subsequent 5 years to develop thyroid dysfunction.  
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Guidelines, both in Europe and the USA have proposed that women with TSH>2.5mU/l be defined as 
SCH and treated with thyroxine, but the evidence behind this is mixed, and many would argue 
against the “medicalisation” of such large numbers of women. Treatment of SCH also raises 
questions about whether the treatment should be continued after pregnancy, and how, when and 
by whom it should be reduced. Using an arbitrary cut-off of 2.5mU/l as recommended in current 
guidelines will mean that 12% of women in this cohort, and potentially higher proportions of 
patients in other populations will be defined as SCH,15,16 with differences between ethnic groups.17  
Reflecting recent data indicating that the upper limit of normal first trimester ranges are higher than 
2.5mU/l, 5,18 the forthcoming American Thyroid Association guidelines, first presented in April 2016, 
recommend that an upper limit of 4mU/l be used. 19  
 
Only 88 women with previously known thyroid disease were included in the study, and as such the 
study was not sufficiently powered to show a difference in obstetric outcomes in these women. Of 
them, more than half had a TSH of greater than 2.5mU/l at week 12-14, indicating (according to 
guideline recommendations) that they were under-replaced. Guidelines indicating that thyroxine 
dose should be increased by 30% in early pregnancy 6,7 have not always come into routine clinical 
practice, particularly in primary care where most hypothyroid women contemplating pregnancy are 
managed.  
 
In this large study of otherwise healthy pregnant women we have shown that a significant 
proportion fall into the category where they would be diagnosed with subclinical hypothyroidism, 
reflecting other studies using the same diagnostic cut-offs. 15,18 Although maternal thyroid antibody 
status was not checked, making accurate interpretation of thyroid function less reliable, this 
situation reflects real-life practice where clinicians have to decide on treatment without such 
information. We found that the majority of women with TSH >2.5mU/l do not go on to have further 
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thyroid problems. Although this may be an underestimate (since the majority of women have not 
been tested,) our results reflect those of a previous study which reported that 75% of women with 
SCH in pregnancy have normal thyroid function at five years of follow-up. 20 The study has some 
limitations. Since the overall study was designed only to examine obstetric outcomes, there was no 
information regarding IQ or other long-term outcomes of the offspring. Thyroid function tests from 
pregnancy and analysis of pregnancy outcomes was not available in all women, although there was 
no demonstrable difference between these women and the rest of the cohort (Supplementary Table 
1 & 2.)  
 
The question of whether women should be screened for thyroid dysfunction continues. It is clear 
that there is a requirement for local trimester-specific and ethnicity-specific reference ranges. 
Classification of large numbers of women as having SCH would have major implications for the 
planning and costing of obstetric services, and given the mixed message from the guidelines, further 
evidence of the benefits of treating SCH is required before such treatment can come into routine 
clinical practice.  
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